Comparative Pharmacology
Head-to-head clinical analysis: ATENOLOL versus CORGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATENOLOL versus CORGARD.
ATENOLOL vs CORGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects.
Nonselective beta-adrenergic receptor antagonist; competitively blocks beta1- and beta2-adrenergic receptors, leading to decreased heart rate, myocardial contractility, and blood pressure. Also prolongs sinoatrial node refractory period and inhibits renin release.
50 mg orally once daily; may increase to 100 mg orally once daily if needed.
40 mg orally once daily for hypertension; initial dose 40 mg once daily for angina, titrate up to 80-240 mg once daily. Maximum dose 320 mg/day.
None Documented
None Documented
Clinical Note
moderateAtenolol + Digoxin
"Atenolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateAtenolol + Digitoxin
"Atenolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateAtenolol + Deslanoside
"Atenolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateAtenolol + Acetyldigitoxin
"Atenolol may increase the bradycardic activities of Acetyldigitoxin."
6-9 hours (terminal elimination half-life); may increase to 15-30 hours in renal impairment (CrCl <35 mL/min).
Terminal elimination half-life: 20-24 hours (may extend to 40 hours in renal impairment). Clinical context: Allows once-daily dosing; steady-state achieved in 5-7 days.
Renal: 40-50% unchanged drug; minor hepatic metabolism (10-20%) with biliary excretion of metabolites; <5% fecal.
Renal (unchanged, ~85-90%); fecal (<5%); biliary (<2%).
Category C
Category C
Beta-Blocker
Beta-Blocker